McKesson Near a Record High Still Has Earnings Support, Not a Safety Guarantee

McKesson traded at $980.88 on October 29, 2026, less than 5% below its October 20 closing high of $1,030.12. A high price can make a stock feel dangerous, but the relevant question is whether earnings and contracts have strengthened enough to support it.

The company's latest completed quarter provided evidence. Fiscal first-quarter 2027 revenue rose 8% to $105.4 billion. Reported earnings per diluted share fell to $5.15 from $6.25, while adjusted earnings per diluted share rose 20% to $9.93. The difference is important because adjusted results exclude items that affected reported profit.

Growth came from both North American Pharmaceutical distribution and Oncology & Multispecialty, helped by prescription volume and specialty products. McKesson also raised full-year adjusted earnings guidance to $44.20 to $45.00 a share and increased the quarterly dividend 15% to $0.94. The company had returned $2.6 billion to shareholders during the quarter, including a $2.25 billion accelerated share repurchase.

A contract announcement reduced another source of uncertainty. On October 1, McKesson reached an agreement in principle to extend its pharmaceutical distribution relationship with CVS Health through June 2032. The arrangement covers mail-order and specialty pharmacies, retail pharmacies and distribution centers. Because it was an agreement in principle, investors should still distinguish the announced extension from final definitive documentation.

The source analysis also tested what happened after prior highs. It identified 12 earlier 52-week highs from October 2016 through October 2025, counted no more than once every 126 trading sessions. McKesson was higher 252 trading sessions later after 11 of the 12 observations, with a median gain of 19.1%. The median result after any trading day in the same period was 23.1%.

That history is useful context, not a forecast. The worst observation followed the January 2018 high, when the stock was down 27.6% a year later. Three of the 12 highs were followed by a decline of at least 20% at some point during the next year. The sample is small, excludes dividends and can be influenced by the strong trend in McKesson's business.

Valuation had not expanded as quickly as the share price, according to the source. It calculated a price-to-earnings multiple of about 25.4, down from roughly 32 a year earlier, because trailing net income grew faster than the stock. That calculation should be checked again after each report, since reported and adjusted earnings produce different multiples.

Buying near a high is therefore neither automatically reckless nor automatically safe. McKesson's earnings growth, specialty exposure and CVS extension provide business support. The risks are customer concentration, pharmaceutical distribution economics, execution in oncology and the possibility that adjusted growth does not translate into reported profit and cash flow. The November 4 fiscal second-quarter report is the next direct test.